Assessment of functional performance in Chagas heart disease by Human Activity Profile questionnaire

References

• Nunes MCP, Beaton A, Acquatella H. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018;138:e169–e209.
   PubMed Web of Science ®Google Scholar
• Botoni FA, Ribeiro AL, Marinho CC, et al. Treatment of Chagas cardiomyopathy. BioMed Res Int. 2013;2013:1.
   Web of Science ®Google Scholar
• Bestetti RB, Muccillo G. Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol. 1997;60:187–193.
   PubMed Web of Science ®Google Scholar
• Rocha MO, Teixeira MM, Ribeiro AL. An update on the management of Chagas cardiomyopathy. Expert Rev Anti-Infect Ther. 2007;5:727–743.
   PubMed Web of Science ®Google Scholar
• Martins-Melo FR, Ramos AN Jr, Alencar CH, et al. Prevalence of Chagas disease in Brazil: a systematic review and meta-analysis. Acta Trop. 2014;130:167–174.
   PubMed Web of Science ®Google Scholar
• Gascon J, Bern C, Pinazo M-J. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115:22–27.
   PubMed Web of Science ®Google Scholar
• Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003540.
   PubMed Web of Science ®Google Scholar
• Mady C, Ianni BM, Arteaga E, et al. Maximal functional capacity in patients with Chagas’ cardiomyopathy without congestive heart failure. J Card Fail. 2000;6:220–224.
   PubMed Web of Science ®Google Scholar
• Costa HS, Lima MMO, Costa F, et al. Reduced functional capacity in patients with Chagas disease: a systematic review with meta-analysis. Rev Soc Bras Med Trop. 2018;51:421–426.
   PubMed Web of Science ®Google Scholar
• Costa HS, Lima MMO, Figueiredo PHS, et al. The prognostic value of health-related quality of life in patients with Chagas heart disease. Qual Life Res. 2018;28:1–6.
   PubMedGoogle Scholar
• Costa HS, Lima MMO, Figueiredo PHS, et al. Prognostic value of serum brain-derived neurotrophic factor levels in patients with Chagas cardiomyopathy. Mem Inst Oswaldo Cruz. 2018;113:e180224.
   PubMed Web of Science ®Google Scholar
• Ritt LE, Carvalho AC, Feitosa GS, et al. Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to Chagas disease. Int J Cardiol. 2013;168:4584–4585.
   PubMed Web of Science ®Google Scholar
• Costa HS, Alves RL, Silva Sa D, et al. Assessment of functional capacity in Chagas heart disease by incremental shuttle walk test and its relation to quality-of-life. Int J Prev Med. 2014;5:152.
   PubMedGoogle Scholar
• Fleg JL, Piña IL, Balady GJ, et al. Assessment of functional capacity in clinical and research applications: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000;102:1591–1597.
   PubMed Web of Science ®Google Scholar
• Costa HS, Lima MMO, Figueiredo PHS, et al. Novel physiotherapies in the setting of Chagas heart disease: a summarized review of functional evaluation. J Novel Physiother. 2018;8:378.
   Google Scholar
• Corder K, Ekelund U, Steele RM, et al. Assessment of physical activity in youth. J Appl Physiol. 2008;105:977–987.
   PubMed Web of Science ®Google Scholar
• Fix A, Daughton D. Human activity profile: professional manual. Odessa (FL): Psychological Assessment Resources Inc.; 1988.
   Google Scholar
• Lage SM, Britto RR, Baião EA, et al. Perfil de atividade humana e capacidade funcional em indivíduos com insuficiência cardíaca crônica. Braz J Phys Ther. 2008;12:39.
   Google Scholar
• Baas LS. Self-care resources and activity as predictors of quality of life in persons after myocardial infarction. Dimensions Crit Care Nurs. 2004;23:131–138.
   PubMedGoogle Scholar
• Ribeiro-Samora GA, Pereira DAG, Vieira OA, et al. Using the Human Activity Profile to assess functional performance in heart failure. J Cardiopulm Rehabil Prev. 2016;36:180–185.
   PubMed Web of Science ®Google Scholar
• Davidson M, de Morton N. A systematic review of the Human Activity Profile. Clin Rehabil. 2007;21:151–162.
   PubMed Web of Science ®Google Scholar
• Daughton D, Fix A, Kass I, et al. Maximum oxygen consumption and the ADAPT quality-of-life scale. Arch Phys Med Rehabil. 1982;63:620.
   PubMed Web of Science ®Google Scholar
• Souza AC, Magalhães LC, Teixeira-Salmela LF. Cross-cultural adaptation and analysis of the psychometric properties in the Brazilian version of the Human Activity Profile. Cad Saúde Pública. 2006;22:2623–2636.
   PubMedGoogle Scholar
• Andrade JPd, Neto M, Antonio J, et al. Latin American Guidelines for the diagnosis and treatment of Chagas’ heart disease: executive summary. Arq Bras Cardiol. 2011;96:434–442.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–271.
   PubMed Web of Science ®Google Scholar
• American College of Sports Medicine. ACSM’s guidelines for exercise testing and exercise prescription. Philadelphia (PA): Lippincott, Williams & Wilkins; 2006.
   Google Scholar
• Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol. 1985;55:A22–A31.
   PubMed Web of Science ®Google Scholar
• Arena R, Myers J, Guazzi M. Cardiopulmonary exercise testing is a core assessment for patients with heart failure. Congestive Heart Fail. 2011;17:115–119.
   PubMedGoogle Scholar
• Mady C, Cardoso R, Barretto A, et al. Survival and predictors of survival in patients with congestive heart failure due to Chagas’ cardiomyopathy. Circulation. 1994;90:3098–3102.
   PubMed Web of Science ®Google Scholar
• Nunes MCP, Carmo AALD, Rocha MOC, et al. Mortality prediction in Chagas heart disease. Expert Rev Cardiovasc Ther. 2012;10:1173–1184.
   PubMedGoogle Scholar
• Rassi A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007;115:1101–1108.
   PubMed Web of Science ®Google Scholar
• Mady C, Yazbek Junior P, Barreto ACP. Estudo da capacidade funcional máxima pela ergoespirometria em pacientes portadores da doença de Chagas. Arq Bras Cardiol. 1986;47:201–205.
   PubMedGoogle Scholar
• Lima MMO, Nunes MCP, Rocha MO, et al. Left ventricular diastolic function and exercise capacity in patients with Chagas cardiomyopathy. Echocardiography. 2010;27:519–524.
   PubMed Web of Science ®Google Scholar
• Mady C, Cardosa R, Ianni BM, et al. Normal maximal functional capacity in patients with congestive heart failure due to Chagas’ cardiomyopathy. Arq Bras Cardiol. 1996;67:1–4.
   PubMedGoogle Scholar
• Grewal J, McCully RB, Kane GC, et al. Left ventricular function and exercise capacity. JAMA. 2009;301:286–294.
   PubMedGoogle Scholar
• Snoer M, Monk-Hansen T, Olsen RH, et al. Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure. Eur Heart J – Cardiovasc Imaging. 2013;14:677–683.
   PubMed Web of Science ®Google Scholar
• Van de Veire NR, De Winter O, Philippé J, et al. Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler–derived systolic and diastolic function. Am Heart J. 2006;152:297.e1–297.e7.
   Web of Science ®Google Scholar
• Oliveira BG, Abreu MNS, Abreu CDG, et al. Health-related quality of life in patients with Chagas disease. Rev Soc Bras Med Trop. 2011;44:150–156.
   PubMed Web of Science ®Google Scholar